|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu W, Xu B, Yao Y, Yu X, Cao H, Zhang J,
Liu J and Sheng H: Overexpression and biological function of IQGAP3
in human pancreatic cancer. Am J Transl Res. 8:5421–5432.
2016.PubMed/NCBI
|
|
3
|
Yao W, Ji S, Qin Y, Yang J, Xu J, Zhang B,
Xu W, Liu J, Shi S, Liu L, et al: Profilin-1 suppresses
tumorigenicity in pancreatic cancer through regulation of the
SIRT3-HIF1α axis. Mol Cancer. 13:1872014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xiao H, Tang K, Liu P, Chen K, Hu J, Zeng
J, Xiao W, Yu G, Yao W, Zhou H, et al: LncRNA MALAT1 functions as a
competing endogenous RNA to regulate ZEB2 expression by sponging
miR-200s in clear cell kidney carcinoma. Oncotarget. 6:38005–38015.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsai MC, Manor O, Wan Y, Mosammaparast N,
Wang JK, Lan F, Shi Y, Segal E and Chang HY: Long noncoding RNA as
modular scaffold of histone modification complexes. Science.
329:689–693. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fatica A and Bozzoni I: Long non-coding
RNAs: New players in cell differentiation and development. Nat Rev
Genet. 15:7–21. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Prensner JR and Chinnaiyan AM: The
emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li CH and Chen Y: Targeting long
non-coding RNAs in cancers: Progress and prospects. Int J Biochem
Cell Biol. 45:1895–1910. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mei D, Song H, Wang K, Lou Y, Sun W, Liu
Z, Ding X and Guo J: Up-regulation of SUMO1 pseudogene 3 (SUMO1P3)
in gastric cancer and its clinical association. Med Oncol.
30:7092013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhan Y, Liu Y, Wang C, Lin J, Chen M, Chen
X, Zhuang C, Liu L, Xu W, Zhou Q, et al: Increased expression of
SUMO1P3 predicts poor prognosis and promotes tumor growth and
metastasis in bladder cancer. Oncotarget. 7:16038–16048. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin C, Zhao GC, Xu YD, Wang DS, Jin DY, Ji
Y, Lou WH and Wu WC: Increased expression of αTubulin is associated
with poor prognosis in patients with pancreatic cancer after
surgical resection. Oncotarget. 7:60657–60664. 2016.PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu X, Sood AK, Dang CV and Zhang L: The
role of long noncoding RNAs in cancer: The dark matter matters.
Curr Opin Genet Dev. 48:8–15. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao L, Kong H, Sun H, Chen Z, Chen B and
Zhou M: LncRNA-PVT1 promotes pancreatic cancer cells proliferation
and migration through acting as a molecular sponge to regulate
miR-448. J Cell Physiol. 233:4044–4055. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qin CF and Zhao FL: Long non-coding RNA
TUG1 can promote proliferation and migration of pancreatic cancer
via EMT pathway. Eur Rev Med Pharmacol Sci. 21:2377–2384.
2017.PubMed/NCBI
|
|
16
|
Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H,
Kong J, Ding K, Shen HM, Wu H, et al: Long non-coding RNA linc00673
regulated non-small cell lung cancer proliferation, migration,
invasion and epithelial mesenchymal transition by sponging
miR-150-5p. Mol Cancer. 16:1182017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang C, Xie D, Cui J, Li Q, Gao Y and Xie
K: FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal
transition and metastasis via upregulation of expression of the
urokinase plasminogen activator system. Clin Cancer Res.
20:1477–1488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma R, Chen J, Jiang S, Lin S, Zhang X and
Liang X: Up regulation of NAT10 promotes metastasis of
hepatocellular carcinoma cells through epithelial-to-mesenchymal
transition. Am J Transl Res. 8:4215–4223. 2016.PubMed/NCBI
|
|
19
|
Tam WL and Weinberg RA: The epigenetics of
epithelial-mesenchymal plasticity in cancer. Nat Med. 19:1438–1449.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu JF, Mao L, Bu LL, Ma SR, Huang CF,
Zhang WF and Sun ZJ: C4.4A as a biomarker of head and neck squamous
cell carcinoma and correlated with epithelial mesenchymal
transition. Am J Cancer Res. 5:3505–3515. 2015.PubMed/NCBI
|
|
21
|
Guo F, Kerrigan Parker BC, Yang D, Hu L,
Shmulevich I, Sood AK, Xue F and Zhang W: Post-transcriptional
regulatory network of epithelial-to-mesenchymal and
mesenchymal-to-epithelial transitions. J Hematol Oncol. 7:192014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shan ZZ, Yan XB, Yan LL, Tian Y, Meng QC,
Qiu WW, Zhang Z and Jin ZM: Overexpression of Tbx3 is correlated
with Epithelial-Mesenchymal Transition phenotype and predicts poor
prognosis of colorectal cancer. Am J Cancer Res. 5:344–353.
2014.PubMed/NCBI
|
|
23
|
Dai C, Cao J, Zeng Y, Xu S, Jia X and Xu
P: E-cadherin expression as a prognostic factor in patients with
ovarian cancer: A meta-analysis. Oncotarget. 8:81052–81061. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang X, Liu G, Kang Y, Dong Z, Qian Q and
Ma X: N-cadherin expression is associated with acquisition of EMT
phenotype and with enhanced invasion in erlotinib-resistant lung
cancer cell lines. PLoS One. 8:e576922013. View Article : Google Scholar : PubMed/NCBI
|
